Animal Cell, Per Se (e.g., Cell Lines, Etc.); Composition Thereof; Process Of Propagating, Maintaining Or Preserving An Animal Cell Or Composition Thereof; Process Of Isolating Or Separating An Animal Cell Or Composition Thereof; Process Of Preparing A Composition Containing An Animal Cell; Culture Media Therefore Patents (Class 435/325)
Animal cell, per se, expressing immunoglobulin, antibody, or fragment thereof (Class 435/326)
Fused or hybrid cell, per se (Class 435/346)
Two or more cell types, per se, in co-culture (Class 435/347)
Insect cell, per se (Class 435/348)
Avian cell, per se (Class 435/349)
Canine cell, per se (Class 435/350)
Feline cell, per se (Class 435/351)
Rodent cell, per se (Class 435/352)
Primate cell, per se (Class 435/363)
Method of co-culturing cells (Class 435/373)
Method of storing cells in a viable state (Class 435/374)
Method of regulating cell metabolism or physiology (Class 435/375)
Method of detaching cells, digesting tissue or establishing a primary culture (Class 435/378)
Method of culturing encapsulated cells (Class 435/382)
Method of culturing cells in suspension (Class 435/383)
Solid support and method of culturing cells on said solid support (Class 435/395)
Culture medium, per se (Class 435/404)
  • Reversibly masked polymers
    Patent number: 10022456
    Abstract: The present invention is directed to reversibly inactivated membrane active polymers useful for cellular delivery of compounds. Described are polyconjugate systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: July 17, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: David B Rozema, Jon A Wolff, James E Hagstrom, Kirk Ekena
  • Cell rolling separation
    Patent number: 10011817
    Abstract: The present invention provides systems for cell separation based on cell rolling on surfaces along edges of regions coated with cell adhesion molecules. A variety of designs of coated regions and edges are disclosed.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: July 3, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Rohit Nandkumar Karnik, Seungpyo Hong, Ying Mei, Daniel Griffith Anderson, Jeffrey Michael Karp, Robert S. Langer, Suman Bose
  • Integrated cement delivery system for bone augmentation procedures and methods
    Patent number: 10004549
    Abstract: A method for preparing a bone including percutaneously forming a path to the cancellous bone using a multi-lumen cannula, providing a first passage to the cancellous bone in a central lumen and a second passage in a concentric outer lumen, introducing a rinsing fluid in one of the passages to rinse bone marrow and other soft tissue from the cancellous bone, and removing the rinsed bone marrow from the other passage. Also, a method for percutaneously treating a tissue affected by a lesion, including introducing a rinsing fluid in one of the passages to rinse the lesion and removing the rinsed lesion from the other of the passages. Also, a method of treating tissue with a lesion including introducing a thick flowable material through one lumen of the cannula and applying suction through the other lumen of the cannula.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: June 26, 2018
    Inventor: Gamal Baroud
  • Culture medium and method for inducing differentiation of pluripotent stem cells to hepatoblasts
    Patent number: 10006005
    Abstract: Provided are a method of inducing differentiation of pluripotent stem cells, such as induced pluripotent stem cells (hereinafter abbreviated as iPS cells), to hepatocytes in a short period of time, and a substance to be used in the method. Specifically, provided are a method of producing a cell culture formed substantially of hepatoblasts, the method including culturing pluripotent stem cells, such as iPS cells, in a culture medium having a composition shown in Table 1 below, and a culture medium for inducing differentiation of pluripotent stem cells into hepatoblasts, which has a composition shown in Table 1 below.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: June 26, 2018
    Assignee: National University Corporation Chiba University
    Inventor: Minoru Tomizawa
  • Culture medium of adipose-derived stem cell, method for preparing the same, and composition including the same for promoting hair growth
    Patent number: 9999589
    Abstract: Provided are a culture medium of an adipose-derived stem cell, a method for preparing the same, and a composition for promoting hair growth, in which the composition includes the culture medium. The adipose-derived stem cell (ADSC-T) according to the present invention exhibits long lifespan, improved cell proliferation rate, and extended proliferation period, as compared with a primary adipose-derived stem cell (ADSC), and thus, the adipose-derived stem cell (ADSC-T) can be usefully used for the study about the adipose-derived stem cell and the mass production of the culture medium of the adipose-derived stem cell. In addition, according to the present invention, the culture medium of the adipose-derived stem cell (ADSC-T) that expresses a T antigen of SV40 exhibits excellent hair growth effectiveness and can be usefully used as a raw material for the hair loss prevention and hair growing agents.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: June 19, 2018
    Assignee: CHANGWON NATIONAL UNIVERSITY INDUSTRY ACADEMY COOP
    Inventors: Dong Wan Kim, Mi Jung Seo, Gwang Lee, Woo Hong Joo, Sun Hee Kim
  • Methods for culturing undifferentiated cells using sustained release compositions
    Patent number: 9994826
    Abstract: Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: June 12, 2018
    Assignee: Regenerative Research Foundation
    Inventors: Sally Temple Stern, Jeffrey Stern
  • Self-regulated peptide hydrogel for insulin delivery
    Patent number: 9994615
    Abstract: A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: June 12, 2018
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Robert S. Langer, Daniel G. Anderson, Zhen Gu, Alex Arthur Aimetti
  • Use of escin
    Patent number: 9993512
    Abstract: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: June 12, 2018
    Assignee: MARINOMED BIOTECHNOLOGIE GMBH
    Inventors: Andreas T. Grassauer, Eva Prieschl
  • Antisense design
    Patent number: 9994850
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 12, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
  • Miniature swine transgenic for one or more coagulation factors
    Patent number: 9980471
    Abstract: Transgenic swine that express human coagulation factors, e.g., human coagulation factor VII, and/or one or more of human coagulation factors II, X and XII, and do not express the corresponding porcine coagulation factor or factors, as well as cells, tissues and organs derived therefrom, and their use in transplantation procedures.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: May 29, 2018
    Assignee: The General Hospital Corporation
    Inventors: David H. Sachs, Martin Hertl
  • Vascularized porous metal orthopaedic implant devices
    Patent number: 9980819
    Abstract: An osteoconductive vascularized porous metal implant device and method for implanting the vascularized device are described herein. The vascularized implant device comprises an implant which is porous titanium, tantalum or other metal which is biocompatible with the mammalian body and at least one vascular conduit which connects the porous implant to an animal vasculature, such as a human vascular system.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: May 29, 2018
    Inventor: Robert R. Gray
  • Cell compositions derived from dedifferentiated reprogrammed cells
    Patent number: 9982235
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: May 29, 2018
    Assignee: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Polymers which resist bacterial attachment
    Patent number: 9981068
    Abstract: The invention provides a method for inhibiting bacterial attachment to a surface, the method comprising forming the surface from a polymer, or applying a polymer to the surface, wherein the polymer is a homopolymer formed from a (meth) acrylate or (meth) acrylamide monomer or a copolymer formed from one or more (meth) acrylate or (meth) acrylamide monomers, wherein the (meth) acrylate or (meth) acrylamide monomers are of formula (I) or (II): [H2C?CR?—C(?O)—O—]nR??(I) [H2C?CR?—C(?O)—NH—]nR??(II) wherein n is 1, 2 or 3, R? is independently H or CH3, R is an organic group having a total of from 2 to 24 carbon atoms, wherein the organic group includes an aliphatic or aromatic hydrocarbon moiety and wherein the organic group does not include any hydroxyl groups.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: May 29, 2018
    Assignees: The University of Nottingham, Massachusetts Institute of Technology
    Inventors: Paul Williams, Morgan Russell Alexander, Martyn Christopher Davies, Robert Langer, Daniel Griffith Anderson
  • Methods for purifying cells derived from pluripotent stem cells
    Patent number: 9969981
    Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention provides methods of characterization of cells differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage utilizing unique surface markers. The present invention also provides methods to enrich or sort cells expressing markers characteristic of the pancreatic endocrine lineage. The present invention also provides methods to deplete cells that may contaminate populations of cells expressing markers characteristic of the pancreatic endocrine lineage formed by the methods of the present invention, thereby reducing the incidence of tumor formation in vivo following transplantation.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: May 15, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Francis Karanu, Alireza Rezania
  • Pluripotent stem cell culture on micro-carriers
    Patent number: 9969972
    Abstract: The present invention is directed to methods for the growth, expansion and differentiation of pluripotent stem cells on micro-carriers.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: May 15, 2018
    Assignee: Janssen Biotech, Inc.
    Inventor: Shelley Nelson
  • Silylated biomolecule-based hydrogel for culturing cardiomyocytes and stem cells, and use of the hydrogel thereof for treating heart failure
    Patent number: 9968681
    Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: May 15, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes, CHU Nantes
    Inventors: Pierre Weiss, Eva Mathieu, Jérôme Guicheux, Patricia Lemarchand
  • Methods for modulating C9ORF72 expression
    Patent number: 9963699
    Abstract: Disclosed herein are methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: May 8, 2018
    Assignees: Ionis Pharmaceuticals, Inc., Ludwig Institute for Cancer Research, The Regents of the University of California
    Inventors: C. Frank Bennett, Susan M. Freier, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • Differentiation of human embryonic stem cells
    Patent number: 9951314
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells, wherein greater than 80% of the cells in the population express markers characteristic of the definitive endoderm lineage.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 24, 2018
    Assignee: Janssen Biotech, Inc.
    Inventor: Benjamin Fryer
  • Composition for reducing senescence of cell or subject comprising smurf2 inhibitor and use thereof
    Patent number: 9951336
    Abstract: A composition for reducing a level of senescence of a cell or subject, a method of reducing a level of senescence in a cell or subject by using the composition, and a method of preventing and treating symptoms or diseases related to or caused by senescence of a cell or subject.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: April 24, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Kobong Choi, Joontae Park, Hyuntae Kang
  • Biomolecular cell encapsulation device and methods of implantation
    Patent number: 9950149
    Abstract: Provided herein is a cell encapsulation device comprising an internal chamber suitable for holding biological agents, wherein the internal chamber is disposed between a first semipermeable layer and a second semi-permeable layer, and the first and second semi-permeable layers are mounted on a supporting frame surrounding a perimeter of the internal chamber; wherein the supporting frame comprises a first frame element and a second frame element, and the first and second frame elements co-operate to position the first and second semipermeable layers at a predetermined separation distance between the layers.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: April 24, 2018
    Assignees: NESTEC S.A., ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
    Inventors: Aurelien Lathuiliere, Nicolas Bouche, Bernard Schneider
  • 2?-methoxy substituted oligomeric compounds and compositions for use in gene modulations
    Patent number: 9943538
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2?-OCH3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 17, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Method for cell culture
    Patent number: 9944895
    Abstract: A method for stem or progenitor cell culture. More precisely, the invention relates to a method for cell culture using one or more I?I (inter-alpha trypsin inhibitor or inter-alpha inhibitor) protein(s) or part(s) thereof as a component in a cell culture media or a coating on a cell culture surface material. Furthermore the invention relates to a cell culture media and a cell culture coating/matrix provided with one or more I?I proteins(s) or part(s) thereof.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: April 17, 2018
    Assignee: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Sara Pijuan Galito, Christoffer Tamm, Cecilia Anneren
  • 2?-methoxy substituted oligomeric compounds and compositions for use in gene modulations
    Patent number: 9943539
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2?-OCH3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 17, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Tissue-specific extracellular matrix with or without tissue protein components for cell culture
    Patent number: 9938502
    Abstract: The present invention relates to compositions and methods for mimicking an in vivo environment for culturing cells in vitro. The in vivo mimicking environment is based on the generation of a tissue-specific extracellular matrix wherein the matrix provides a substrate for which the cultured cell originated from. The tissue-specific extracellular matrix can further comprise a component of a whole tissue-specific homogenate.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: April 10, 2018
    Assignee: Wake Forest University Health Sciences
    Inventors: Yuanyuan Zhang, Shay Soker, Anthony Atala, Aleksander Skardal
  • T cell receptor-deficient T cell compositions
    Patent number: 9938497
    Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: April 10, 2018
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventor: Charles L. Sentman
  • Methods for preventing and treating chronic kidney disease (CKD)
    Patent number: 9926562
    Abstract: The present invention relates to methods for preventing and treating chronic kidney disease (CKD).
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: March 27, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSITANCE PUBLIQUE—HOPITAUX DE PARIS, INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Christos Chatziantoniou, Jean-Claude Dussaule, Simon J. Conway
  • Combined chemical and genetic approaches for generation of induced pluripotent stem cells
    Patent number: 9926533
    Abstract: The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: March 27, 2018
    Assignee: The Scripps Research Institute
    Inventors: Yan Shi, Caroline Desponts, Sheng Ding, Hongyan Zhou, Tongxiang Lin, Wenlin Li, Saiyong Zhu
  • Method of generating induced pluripotent stem cells and differentiated cells
    Patent number: 9926532
    Abstract: Methods for generating iPSCs and differentiated cells of interest by reprogramming donor cells that have been obtained in a non-invasive manner. In particular, the donor cells are exfoliated epithelial urine cells. The differentiated cells can be obtained by differentiation of the reprogrammed iPSCs or by direct reprogramming the urine cells.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: March 27, 2018
    Assignees: Guangzhou Institute of Biomedicine and Health, Universitat fur Bodenkultur Wien
    Inventors: Miguel Esteban, Johannes Grillari, Regina Grillari, Duanqing Pei, Ting Zhou
  • Method of making induced pluripotent stem cells
    Patent number: 9920333
    Abstract: Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: March 20, 2018
    Assignee: University of Utah Research Foundation
    Inventors: Stefan M. Pulst, Sharan Paul, Warunee Dansithong
  • Induction of germ cells from pluripotent cells
    Patent number: 9920300
    Abstract: Methods and compositions are provided for promoting germ cell differentiation from pluripotent cells, and for identifying agents that modulate germ cell differentiation.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: March 20, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Keh Kooi Kee, Renee A. Reijo Pera
  • Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
    Patent number: 9914923
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors.
    Type: Grant
    Filed: January 1, 2015
    Date of Patent: March 13, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Method of introducing a toxin or dye into mammalian pluripotent cells using rBC2LCN
    Patent number: 9914908
    Abstract: An object of the present invention is to provide a method for introducing a target substance into undifferentiated cells, and a carrier therefor, whereby the target substance can be specifically introduced into the undifferentiated cells by contacting the undifferentiated cells with an rBC2LCN-target substance fusion product in which rBC2LCN lectin is fused to the target substance. Particularly, an rBC2LCN-toxin fusion product in which rBC2LCN lectin is fused to a toxin functioning in cells or its domain having the ability to kill cells functions as an agent for eliminating undifferentiated stem cells and can be administered into a medium after inducing the differentiation of the stem cells to reliably kill only the stem cells in an undifferentiated state.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: March 13, 2018
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Hiroaki Tateno, Yuzuru Ito, Yasuko Onuma, Jun Hirabayashi, Makoto Asashima
  • Detection of ovarian cancer using antibody arrays
    Patent number: 9897608
    Abstract: Disclosed are antibody arrays for the detection of cancer in a human or animal subject, comprising a solid support having disposed thereon in a predetermined spatial configuration, a panel of antibodies specific to biomarkers comprising CA-125, MSP-?, TIMP-4, PDGF-R? and OPG, wherein the panel comprises a first antibody or fragment thereof that specifically binds CA-125, a second antibody or fragment thereof that specifically binds MSP-?, a third antibody or fragment thereof that specifically binds TIMP-4, a fourth antibody or fragment thereof that specifically binds PDGF-R?, and a fifth antibody or fragment thereof that specifically binds OPG. Also disclosed are systems containing the arrays and methods of using the arrays to detect cancer such as ovarian cancer.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: February 20, 2018
    Assignees: Raybiotech, Inc. Guangzhou, SOUTH CHINA BIOCHIP RESEARCH CENTER IN GUANGZHOU
    Inventors: Ruopan Huang, Weidong Jiang, Ruochun Huang
  • Methods, kits, and compositions for stem cell self-renewal
    Patent number: 9896659
    Abstract: Methods and kits for expanding a stem cell population, particularly a hematopoietic stem cell population, in the presence of a DNA methyltransferase modulator and a Wnt pathway modulator are disclosed.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: February 20, 2018
    Assignee: STOWERS INSTITUTE FOR MEDICAL RESEARCH
    Inventors: John M Perry, Linheng Li, Aparna Venkatraman, Xi He
  • Leukaemia stem cell line, its method of production and uses thereof
    Patent number: 9896663
    Abstract: Bromodomain and extra terminal protein (BET) resistant leukemic cell lines and methods for producing such cell lines are described as are methods for using such cell lines in screening assays to identify therapeutic agents. The cell lines can be generated from haematopoietic stem and progenitor cells (HSPCs) that are clonally enriched by serially exposing c-kit positive cells to a BET inhibitor.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: February 20, 2018
    Assignee: Peter MacCallum Cancer Institute
    Inventors: Mark A. Dawson, Chun Yew Fong
  • Use of G-CSF in in vitro embryo culture
    Patent number: 9890356
    Abstract: An in vitro culture medium for embryos consisting of IVF culture medium additionally containing G-CSF at a concentration of at least 0.5 ng/ml, preferably between 1.0 and 5.0 ng/ml, is described; a method for in vitro embryo culture, comprising the steps of incubating a plurality of embryos in an in vitro culture medium consisting of IVF culture medium additionally containing G-CSF at a concentration of at least 0.5 ng/ml and growing such embryos until the 8-cell stage is reached is also described.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: February 13, 2018
    Inventors: Fabio Scarpellini, Marco Sbracia
  • Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
    Patent number: 9890395
    Abstract: Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: February 13, 2018
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Trevor Collingwood, Gregory J. Cost
  • Method for the oral/mucosal vaccination by means of recombinant yeasts
    Patent number: 9885052
    Abstract: Recombinant yeast cells are produced which are used for vaccination, among other uses for the oral vaccination by feeding.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: February 6, 2018
    Assignee: Martin-Luther-Universitaet Halle-Wittenberg
    Inventors: Karin Breunig, Sven-Erik Behrens
  • Maintenance medium for primate pluripotent stem cells
    Patent number: 9883669
    Abstract: Provided are a maintenance medium for primate pluripotent stem cells, and a method for preserving and a method for controlling proliferation of primate pluripotent stem cells using the medium. The maintenance medium for human pluripotent stem cells according to the present invention includes xylose as a saccharide.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: February 6, 2018
    Assignee: BOURBON CORPORATION
    Inventors: Akito Matsushima, Sakiko Takizawa, Tadayuki Yokoyama
  • Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
    Patent number: 9877989
    Abstract: The present invention relates to the use of exosome-preparations derived from neonatal or adult tissue-derived mesenchymal stem-cells (MSCs) for the prevention or for therapy of inflammatory conditions, such as, for example, pre- and postnatally acquired damages of the brain (i.e. neuronal damages) or in complications following stem cell transplantation (“graft vs host-disease”, GvHD).
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: January 30, 2018
    Assignee: UNIVERSITAET DUISBURG-ESSEN
    Inventors: Dietrich Wilhelm Beelen, Thorsten Doeppner, Ursula Felderhoff-Mueser, Bernd Giebel, Dirk Hermann, Peter Horn, Matthias Keller, Lambros Kordelas, Anna-Kristin Ludwig, Vera Rebmann
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9867873
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: January 16, 2018
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Integrated cement delivery system for bone augmentation procedures and methods
    Patent number: 9867646
    Abstract: A method of harvesting bone marrow, including percutaneously introducing a multi-lumen cannula into a cancellous bone, applying suction through a first passage defined in a first lumen of the cannula, injecting a thick flowable material into the bone from a second passage in a second lumen of the cannula, extruding the thick flowable material through a distal end of the cannula into the cancellous bone in order to displace the bone marrow and other bone fluids, the suction applied through the first passage providing a hydraulic force guiding the displaced bone marrow and collecting the displaced bone marrow for a therapeutic or diagnostic purpose. A thick flowable material for use in harvesting bone marrow in the cancellous portion of a bone and a method for percutaneously preparing a bone with a multi-lumen cannula and an inflatable device are also discussed.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: January 16, 2018
    Inventor: Gamal Baroud
  • Method of inducing differentiation from pluripotent stem cells to skeletal muscle cells
    Patent number: 9862929
    Abstract: The present invention provides a method of producing a skeletal muscle cell from a pluripotent stem cell, which includes a step of expressing one or more exogenous factors selected from MyoD, Myf5 and nucleic acids encoding them on a pluripotent stem cell.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: January 9, 2018
    Assignee: Kyoto University
    Inventors: Hidetoshi Sakurai, Akihito Tanaka, Knut Woltjen, Makoto Ikeya
  • Screening methods for cognitive enhancers
    Patent number: 9863934
    Abstract: The present invention provides methods for identifying cognitive enhancers able to enhance CREB pathway function. Cognitive enhancers identified in accordance with the invention can be used in rehabilitating an animal with cognitive dysfunction and for enhancing memory or normal cognitive performance (ability or function) in the animal.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: January 9, 2018
    Assignee: Dart Neuroscience (Cayman) Ltd.
    Inventors: Timothy P. Tully, Roderick E. M. Scott, Rusiko Bourtchouladze
  • Hybridoma clones and monoclonal antibodies to tetraspanin 8
    Patent number: 9850303
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human TSPAN8 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome purification kits using the antibody.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 26, 2017
    Assignee: The Translational Genomics Research Institute
    Inventor: David Azorsa
  • Process for purifying recombinant circumsporozoite protein
    Patent number: 9849177
    Abstract: The present invention relates to processes for purifying high-quality recombinant Plasmodium falciparum circumsporozoite protein at high yields.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: December 26, 2017
    Assignee: PFENEX INC.
    Inventors: Jeffrey Allen, Ryan Haverstock
  • Pluripotent stem cell that induces repair and regeneration after myocardial infarction
    Patent number: 9844570
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: December 19, 2017
    Assignees: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Fluorescent metal ion indicators with large stokes shifts
    Patent number: 9846168
    Abstract: The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: December 19, 2017
    Assignee: Life Technologies Corporation
    Inventors: Kyle Gee, Vladimir Martin
  • Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
    Patent number: 9840730
    Abstract: An isolated polynucleotide encoding a modified luciferase polypeptide and substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type Oplophorus luciferase.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: December 12, 2017
    Assignee: PROMEGA CORPORATION
    Inventors: Brock Binkowski, Lance P. Encell, Mary Hall, Matthew B. Robers, Michael R. Slater, Keith V. Wood, Monika G. Wood
  • Methods of expanding embryonic stem cells in a suspension culture
    Patent number: 9834749
    Abstract: A method of expanding and maintaining human embryonic stem cells (ESCs) in an undifferentiated state by culturing the ESCs in a suspension culture under culturing conditions devoid of substrate adherence is provided. Also provided are a method of deriving ESC lines in the suspension culture and methods of generating lineage-specific cells from ESCs which were expanded in the suspension culture of the present invention.
    Type: Grant
    Filed: May 25, 2015
    Date of Patent: December 5, 2017
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor